HBM Holdings Limited (2142.HK)
| Previous close | 1.240 |
| Open | 1.280 |
| Bid | 1.180 x N/A |
| Ask | 1.200 x N/A |
| Day's range | 1.170 - 1.280 |
| 52-week range | 1.010 - 2.030 |
| Volume | |
| Avg. volume | 1,295,474 |
| Market cap | 870.812M |
| Beta (5Y monthly) | 1.47 |
| PE ratio (TTM) | 5.13 |
| EPS (TTM) | 0.230 |
| Earnings date | 28 Mar 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 1.72 |
PR NewswireHarbour BioMed Reports Full Year 2023 Financial Results
Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immune-oncology and immunology, released annual financial results of full year 2023.
PR NewswireNona Biosciences Enters into Collaboration Agreement with Boostimmune in Antibody-Drug Conjugate Development
Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited committed to cutting-edge technology innovations and providing a total solution from "Idea to IND" ("I to ITM"), announced today that it has entered into a collaboration agreement with Boostimmune, a biotech company dedicated to developing next-generation anti-cancer therapies via modulating immune systems. The collaboration aims to leverage Nona's proprietary Harbour Mice® H2L2 (two light and two heavy chain) platform to accele
- PR Newswire
Harbour BioMed Announces IND Clearance for HBM9027 in the U.S.
Harbour BioMed (the "Company", HKEX: 02142) announced that the Company has been granted the clearance of Investigational New Drug (IND) from the Food and Drug Administration (FDA) of the United States to initiate the first-in-human (FIH) clinical trial in the U.S. for bispecific antibody HBM9027. This is a phase I study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of HBM9027 in subjects with advanced solid tumors.
